The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Open accessAbstract
In pugilistic parlance, the one-two punch is a devastating combination of blows, with the first punch setting the stage and the second delivering the knock-out. This analogy can be extended to molecularly targeted cancer therapies, with oncogene addiction serving to set the stage for tumor cell killing by a targeted therapeutic agent. While in vitro and in vivo examples abound documenting the existence of this phenomenon, the mechanistic underpinnings that govern oncogene addiction are just beginning to emerge. Our current inability to fully exploit this weakness of cancer cells stems from an incomplete understanding of oncogene addiction, which nonetheless represents one of the rare chinks in the formidable armor of cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citationMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis
Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., & Greenberg, M. E. (1995) · Science · doi:10.1126/science.270.5240.1326 · Cited by 5,287
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“…studies demonstrated that this activity required PKC, BCL-2, p53, p16INK4a, p19ARF, NF-kB, and occurred in a caspase-independent manner (Chen and Faller 1995; Rak et al. 1995b; Wang et al. 1995; Miranda et al. 1996; Mayo et al. 1997; Serrano et al. 1997; Chen et GENES & DEVELOPMENT 3219 al.”
BackgroundLessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Bacterial Persistence as a Phenotypic Switch
Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L., & Leibler, S. (2004) · Science · doi:10.1126/science.1099390 · Cited by 2,952 · cited 1×
“Such a drug-tolerant state may be analogous to a state described for various bacterial strains following exposure to antibiotics (Balaban et al. 2004).”
BackgroundInduction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,935
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,409
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
Persister cells, dormancy and infectious disease
Lewis, K. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1557 · Cited by 2,052
Control of apoptosis and mitotic spindle checkpoint by survivin
Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., & Altieri, D. C. (1998) · Nature · doi:10.1038/25141 · Cited by 1,870
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“While translation of this concept to cancer patients remains to be realized, recent studies in transgenic mice provide proof of concept and lend validity to p53 restoration as a cancer therapeutic strategy (Martins et al. 2006; Ventura et al. 2007; Xue et al. 2007).”
BackgroundIAP proteins: blocking the road to death's door
Salvesen, G. S., & Duckett, C. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm830 · Cited by 1,756
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,606
Self-citationHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
A Matter of Life and Cell Death
Evan, G., & Littlewood, T. (1998) · Science · doi:10.1126/science.281.5381.1317 · Cited by 1,523
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
Green, D. R., & Evan, G. I. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00024-7 · Cited by 1,254
Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB
Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., & Evan, G. (1997) · Nature · doi:10.1038/385544a0 · Cited by 1,148
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., et al. (2001) · Nature · doi:10.1038/35051606 · Cited by 966
Harrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O., Nakayama, T., Graham, J. A., Demur, C., Hercend, T., Diu-Hercend, A., et al. (2004) · Nature Medicine · doi:10.1038/nm1003 · Cited by 965
Apoptotic cell death induced by c-myc is inhibited by bcl-2
Bissonnette, R. P., Echeverri, F., Mahboubi, A., & Green, D. R. (1992) · Nature · doi:10.1038/359552a0 · Cited by 957
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936
Pathogenetic mechanisms in thyroid follicular-cell neoplasia
Kondo, T., Ezzat, S., & Asa, S. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1836 · Cited by 893
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., & Vogelstein, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6899 · Cited by 849
p53 and E2F-1 cooperate to mediate apoptosis.
Wu, X., & Levine, A. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3602 · Cited by 839
Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Senescence of human fibroblasts induced by oncogenic Raf
Zhu, J., Woods, D., McMahon, M., & Bishop, J. M. (1998) · Genes & Development · doi:10.1101/gad.12.19.2997 · Cited by 826
Continuous c-fos expression precedes programmed cell death in vivo
Smeyne, R. J., Vendrell, M., Hayward, M., Baker, S. J., Miao, G. G., Schilling, K., Robertson, L. M., Curran, T., & Morgan, J. I. (1993) · Nature · doi:10.1038/363166a0 · Cited by 775
Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.
Qin, X. Q., Livingston, D. M., Kaelin, W. G., & Adams, P. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.10918 · Cited by 756
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R., Yamazaki, S., Koudriakova, T. B., Alton, G., Cui, J. J., Kung, P.-P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4443 · Cited by 745
c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines.
Harrington, E. A., Bennett, M. R., Fanidi, A., & Evan, G. I. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06630.x · Cited by 742
Hypoxia: A key regulator of angiogenesis in cancer
Liao, D., & Johnson, R. S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9066-y · Cited by 721
Role for the p53 homologue p73 in E2F-1-induced apoptosis
Irwin, M., Marin, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., et al. (2000) · Nature · doi:10.1038/35036614 · Cited by 710
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705
Aurora-A — A guardian of poles
Marumoto, T., Zhang, D., & Saya, H. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1526 · Cited by 697
Role for c-myc in Activation-Induced Apoptotic Cell Death in T Cell Hybridomas
Shi, Y., Glynn, J. M., Guilbert, L. J., Cotter, T. G., Bissonnette, R. P., & Green, D. R. (1992) · Science · doi:10.1126/science.1378649 · Cited by 695
Tuveson, D. A., Willis, N. A., Jacks, T., Griffin, J. D., Singer, S., Fletcher, C. D., Fletcher, J. A., & Demetri, G. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204704 · Cited by 695
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C. D., Bishop, J. M., & Felsher, D. W. (2002) · Science · doi:10.1126/science.1071489 · Cited by 644
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
Rabindran, S. K., Discafani, C. M., Rosfjord, E. C., Baxter, M., Floyd, M. B., Golas, J., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2868 · Cited by 639
Woods, D., Parry, D., Cherwinski, H., Bosch, E., Lees, E., & McMahon, M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5598 · Cited by 639
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637 · cited 1×
“3) (Chesi et al. 1997).”
Berger, M. S., Locher, G. W., Saurer, S., Gullick, W. J., Waterfield, M. D., Groner, B., & Hynes, N. E. (1988) · PubMed · Cited by 611
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600
Pleiotropic cell-division defects and apoptosis induced by interference with survivin function
Li, F., Ackermann, E. J., Bennett, C. F., Rothermel, A. L., Plescia, J., Tognin, S., Villa, A., Marchisio, P. C., & Altieri, D. C. (1999) · Nature Cell Biology · doi:10.1038/70242 · Cited by 600
Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582 · cited 1×
“…inducible H-RAS and Ki-RAS oncogenes in mouse tumor models of melanoma and lung adenocarcinoma, respectively, has provided evidence that addiction to the RAS oncoprotein results in tumor cell apoptosis following the acute inactivation of the RAS oncoprotein (Chin et al. 1999; Fisher et al. 2001).”
BackgroundMa, P. C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M. S., Nallasura, V., Fox, E. A., Hansen, M., Schaefer, E., Naoki, K., Lader, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2650 · Cited by 576
Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., & Druker, B. J. (1997) · Blood · doi:10.1182/blood.v90.12.4947 · Cited by 554
The Myc oncoprotein as a therapeutic target for human cancer
Vita, M., & Henriksson, M. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.015 · Cited by 552
Requirement of NF-κB Activation to Suppress p53-Independent Apoptosis Induced by Oncogenic Ras
Mayo, M. W., Wang, C.-Y., Cogswell, P. C., Rogers-Graham, K. S., Lowe, S. W., Der, C. J., & Baldwin, A. S. (1997) · Science · doi:10.1126/science.278.5344.1812 · Cited by 533
Goldman, C. K., Kim, J., Wong, W. L., King, V, Brock, T., & Gillespie, G. Y. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.1.121 · Cited by 531
Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis.
Shan, B., & Lee, W. H. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8166 · Cited by 530
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird, A., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., et al. (2000) · PubMed · Cited by 494
Smolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., Kim, W. J., Okimoto, R. A., Bell, D. W., Sgroi, D. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508776103 · Cited by 485
Self-citationThe tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
Deininger, M. W. N., Goldman, J. M., Lydon, N., & Melo, J. V. (1997) · Blood · doi:10.1182/blood.v90.9.3691 · Cited by 482
Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes & Development · doi:10.1101/gad.1417406 · Cited by 478
Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
Arbiser, J. L., Moses, M. A., Fernandez, C. A., Ghiso, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.3.861 · Cited by 469
Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
Kerbel, R. S. (2006) · Science · doi:10.1126/science.1125950 · Cited by 466
Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.022 · Cited by 462
Van Belle, E., Witzenbichler, B., Chen, D., Silver, M., Chang, L., Schwall, R., & Isner, J. M. (1998) · Circulation · doi:10.1161/01.cir.97.4.381 · Cited by 445
B-RAF is a therapeutic target in melanoma
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207785 · Cited by 426
Kowalik, T. F., DeGregori, J., Schwarz, J. K., & Nevins, J. R. (1995) · Journal of Virology · doi:10.1128/jvi.69.4.2491-2500.1995 · Cited by 418
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase
Manfredi, M. G., Ecsedy, J. A., Meetze, K. A., Balani, S. K., Burenkova, O., Chen, W., Galvin, K. M., Hoar, K. M., Huck, J. J., LeRoy, P. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608798104 · Cited by 413
Golas, J. M., Arndt, K. T., Etienne, C., Lucas, J., Nardin, D., Gibbons, J. J., Frost, P., Ye, F., Boschelli, D. H., & Boschelli, F. (2003) · PubMed · Cited by 408
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 408
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation
Wu, C.-H., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P., & Felsher, D. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701953104 · Cited by 403
Bernhard, E. J., Gruber, S. B., & Muschel, R. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4293 · Cited by 385
(1992) · PubMed · Cited by 383
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Galkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609412103 · Cited by 379
Tsai, K. Y., Hu, Y., Macleod, K. F., Crowley, D., Yamasaki, L., & Jacks, T. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80274-9 · Cited by 372
Matsubara, H., Takeuchi, T., Nishikawa, E., Yanagisawa, K., Hayashita, Y., Ebi, H., Yamada, H., Suzuki, M., Nagino, M., Nimura, Y., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210425 · Cited by 369
Wilkinson, R. W., Odedra, R., Heaton, S. P., Wedge, S. R., Keen, N. J., Crafter, C., Foster, J. R., Brady, M. C., Bigley, A., Brown, E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2979 · Cited by 356
Saleh, M., Stacker, S. A., & Wilks, A. F. (1996) · PubMed · Cited by 354
Cancer gene therapy: fringe or cutting edge?
McCormick, F. (2001) · Nature Reviews Cancer · doi:10.1038/35101008 · Cited by 346
Cheng, S. Y., Huang, H. J., Nagane, M., Ji, X. D., Wang, D., Shih, C. C., Arap, W., Huang, C. M., & Cavenee, W. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8502 · Cited by 342
Strategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334
Microbial phenotypic heterogeneity and antibiotic tolerance
Dhar, N., & McKinney, J. D. (2007) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.12.007 · Cited by 333
Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors
Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., & Robertson, G. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2423 · Cited by 321
Kilic, T., Alberta, J. A., Zdunek, P. R., Acar, M., Iannarelli, P., O'Reilly, T., Buchdunger, E., Black, P. M., & Stiles, C. D. (2000) · PubMed · Cited by 310
Liu, M., Bryant, M., Chen, J., Lee, S., Yaremko, B., Lipari, P., Malkowski, M. G., Ferrari, E., Nielsen, L. L., Prioli, N. A., et al. (1998) · PubMed · Cited by 309
Id proteins in cell growth and tumorigenesis
Sikder, H. A., Devlin, M. K., Dunlap, S., Ryu, B., & Alani, R. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00141-7 · Cited by 309
Maity, A. M., Pore, N., Lee, J. S. H., Solomon, D., & O’Rourke, D. M. (2000) · PubMed · Cited by 302
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
Shepard, H. M., Lewis, G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J., Figari, I., Kotts, C. E., Palladino, M. A., Ullrich, A., et al. (1991) · Journal of Clinical Immunology · doi:10.1007/bf00918679 · Cited by 294
Oncogenic ras and p53 Cooperate To Induce Cellular Senescence
Ferbeyre, G., de Stanchina, E., Lin, A. W., Querido, E., McCurrach, M. E., Hannon, G. J., & Lowe, S. W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3497-3508.2002 · Cited by 290
Trudel, S., Li, Z. H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 289
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., & Lee, T. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.9141 · Cited by 285
Dong, G., Chen, Z., Li, Z. Y., Yeh, N. T., Bancroft, C. C., & Waes, C. V. (2001) · PubMed · Cited by 283
Prenen, H., Cools, J., Mentens, N., Folens, C., Sciot, R., Schöffski, P., Van Oosterom, A., Marynen, P., & Debiec-Rychter, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2275 · Cited by 274
Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis
Weinstein, I. B. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.857 · Cited by 268
Harrington, E. A., Fanidi, A., & Evan, G. I. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90100-7 · Cited by 265
The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal, G. W., Honsawek, S., Litz, J., & Buchdunger, E. (2000) · PubMed · Cited by 265
Ji, H., Zhao, X., Yuza, Y., Shimamura, T., Li, D., Protopopov, A., Jung, B. L., McNamara, K., Xia, H., Glatt, K. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510284103 · Cited by 257
Burgess, T., Coxon, A., Meyer, S., Sun, J., Rex, K., Tsuruda, T., Chen, Q., Ho, S.-Y., Li, L., Kaufman, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3329 · Cited by 252
A role for Jun-N-terminal kinase in anoikis; suppression by bcl-2 and crmA.
Frisch, S. M., Vuori, K., Kelaita, D., & Sicks, S. (1996) · The Journal of cell biology · doi:10.1083/jcb.135.5.1377 · Cited by 248
Chi, S., Kitanaka, C., Noguchi, K., Mochizuki, T., Nagashima, Y., Shirouzu, M., Fujita, H., Yoshida, M., Chen, W., Asai, A., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202538 · Cited by 245
Oncogenes as inducers of tumor angiogenesis
Rak, J., Filmus, J., Finkenzeller, G., Grugel, S., Marm�, D., & Kerbel, R. S. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690598 · Cited by 235
BindingDB (2025) · PubMed · doi:10.7270/q2dv1qm3 · Cited by 235
A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes
Sharma, S. V., Gajowniczek, P., Way, I. P., Lee, D. Y., Jiang, J., Yuza, Y., Classon, M., Haber, D. A., & Settleman, J. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.014 · Cited by 233
Self-citationp53 alterations in human cancer: more questions than answers
Soussi, T. (2007) · Oncogene · doi:10.1038/sj.onc.1210280 · Cited by 232
Activation of p53 in cervical carcinoma cells by small molecules
Hietanen, S., Lain, S., Krausz, E., Blattner, C., & Lane, D. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8501 · Cited by 230
Induction of Apoptosis by c-Fos Protein
Preston, G. A., Lyon, T. T., Yin, Y., Lang, J. E., Solomon, G., Annab, L., Srinivasan, D. G., Alcorta, D. A., & Barrett, J. C. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.1.211 · Cited by 229
Gomez‐Manzano, C., Fueyo-Margareto, J., Kyritsis, A. P., Steck, P. A., Roth, J. A., McDonnell, T. J., Steck, K. D., Levin, V. A., & Yung, W. K. A. (1996) · PubMed · Cited by 228
Hata, T., Furukawa, T., Sunamura, M., Egawa, S., Motoi, F., Ohmura, N., Marumoto, T., Saya, H., & Horii, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3981 · Cited by 217
Cao, B., Su, Y., Oskarsson, M., Zhao, P., Kort, E. J., Fisher, R. J., Wang, L.-M., & Vande Woude, G. F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131200498 · Cited by 213
Hua, J., & Muschel, R. J. (1996) · PubMed · Cited by 211
Switch to the angiogenic phenotype during tumorigenesis.
Folkman, J., & Hanahan, D. (1991) · PubMed · Cited by 200
Sumimoto, H., Miyagishi, M., Miyoshi, H., Yamagata, S., Shimizu, A., Taira, K., & Kawakami, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207812 · Cited by 194
Williams, R. T., Roussel, M. F., & Sherr, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602030103 · Cited by 193
Mulloy, R., Ferrand, A., Kim, Y., Sordella, R., Bell, D. W., Haber, D. A., Anderson, K. S., & Settleman, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4293 · Cited by 192
Self-citationE2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2.
Kowalik, T. F., DeGregori, J. V., Leone, G. W., Jakoi, L., & Nevins, J. R. (1998) · PubMed · Cited by 190
Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA
(1991) · Lung Cancer · doi:10.1016/0169-5002(91)90412-y · Cited by 188
Coupling of Cell Growth Control and Apoptosis Functions of Id Proteins
Norton, J. D., & Atherton, G. T. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.2371 · Cited by 187
Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia
Williams, R. T., den Besten, W., & Sherr, C. J. (2007) · Genes & Development · doi:10.1101/gad.1588607 · Cited by 180
Nistér, M., Claesson-Welsh, L., Eriksson, A., Heldin, C. H., & Westermark, B. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55365-5 · Cited by 178
Boxer, R. B., Jang, J. W., Sintasath, L., & Chodosh, L. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.013 · Cited by 178
Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
Skorski, T., Nieborowska-Skorska, M., Nicolaides, N. C., Szczylik, C., Iversen, P., Iozzo, R. V., Zon, G., & Calabretta, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4504 · Cited by 171
Kondo, S., Asano, M., & Suzuki, H. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1955 · Cited by 168
E2F-1:DP-1 Induces p53 and Overrides Survival Factors To Trigger Apoptosis
Hiebert, S. W., Packham, G., Strom, D. K., Haffner, R., Oren, M., Zambetti, G., & Cleveland, J. L. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6864 · Cited by 163
Trudel, S., Ely, S., Farooqi, Y., Affer, M., Robbiani, D. F., Chesi, M., & Bergsagel, P. L. (2004) · Blood · doi:10.1182/blood-2003-10-3650 · Cited by 162
Roz, L., Gramegna, M., Ishii, H., Croce, C. M., & Sozzi, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062030799 · Cited by 162
PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity
Soncini, C., Carpinelli, P., Gianellini, L., Fancelli, D., Vianello, P., Rusconi, L., Storici, P., Zugnoni, P., Pesenti, E., Croci, V., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1964 · Cited by 162
Bouker, K. B., Skaar, T. C., Riggins, R. B., Harburger, D. S., Fernández, D., Zwart, A. L., Wang, A., & Clarke, R. C. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi113 · Cited by 159
Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074
Grand, E., Chase, A., Heath, C., Rahemtulla, A., & Cross, N. (2004) · Leukemia · doi:10.1038/sj.leu.2403347 · Cited by 158
Yamazaki, H., Ohba, Y., Tamaoki, N., & Shibuya, M. (1990) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1990.tb02644.x · Cited by 158
Developmental Context Determines Latency of MYC-Induced Tumorigenesis
Beer, S., Zetterberg, A., Ihrie, R. A., McTaggart, R., Yang, Q., Bradon, N., Arvanitis, C., Attardi, L. D., Feng, S., Ruebner, B. H., et al. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020332 · Cited by 158
R-Ras promotes apoptosis caused by growth factor deprivation via a Bcl-2 suppressible mechanism.
Wang, H., Millan, J. A., Cox, A. D., Der, C. J., Rapp, U. R., Beck, T., Zha, H., & Reed, J. C. (1995) · The Journal of Cell Biology · doi:10.1083/jcb.129.4.1103 · Cited by 150
Transcriptional control of the endogenous MYC protooncogene by antisense RNA.
Yokoyama, K., & Imamoto, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7363 · Cited by 150
Conditional transgenic models define how MYC initiates and maintains tumorigenesis
Arvanitis, C., & Felsher, D. W. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.012 · Cited by 148
Integrated control of cell proliferation and cell death by the c- myc oncogene
Evan, G. I., Harrington, E. O., Fanidi, A., Land, H., Amati, B. B., & Bennett, M. R. (1994) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1994.0105 · Cited by 147
Rak, J. W., Mitsuhashi, Y., Erdos, V., Huang, S. N., Filmus, J., & Kerbel, R. S. (1995) · The Journal of Cell Biology · doi:10.1083/jcb.131.6.1587 · Cited by 147
Blaskovich, M. A., Lin, Q., Delarue, F. L., Sun, J., Park, H. S., Coppola, D., Hamilton, A. D., & Sebti, S. M. (2000) · Nature Biotechnology · doi:10.1038/80257 · Cited by 143
Zhou, X., Thorgeirsson, S. S., & Popescu, N. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207246 · Cited by 143
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Trudel, S., Stewart, A. K., Rom, E., Wei, E. N., Li, Z. H., Kotzer, S., Chumakov, I., Singer, Y., Chang, H., Liang, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4179 · Cited by 143
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas
Piva, R., Chiarle, R., Manazza, A. D., Taulli, R., Simmons, W. R., Ambrogio, C., d’Escamard, V., Pellegrino, E., Ponzetto, C., Palestro, G., et al. (2005) · Blood · doi:10.1182/blood-2005-05-2125 · Cited by 138
Chen, C. Y., & Faller, D. V. (1995) · PubMed · Cited by 133
Tumor Angiogenesis: Cause or Consequence of Cancer?
Shchors, K., & Evan, G. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2053 · Cited by 132
Shawver, L. K., Schwartz, D. P., Mann, E., et al. (1997) · PubMed · Cited by 131
WWOX gene restoration prevents lung cancer growth in vitro and in vivo
Fabbri, M., Iliopoulos, D., Trapasso, F., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505485102 · Cited by 131
Emanuel, S. L., Rugg, C. A., Gruninger, R. H., Lin, R., Fuentes‐Pesquera, A. R., Connolly, P. J., Wetter, S. K., Hollister, B. A., Kruger, W. W., Napier, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0882 · Cited by 127
Puri, N., Khramtsov, A., Ahmed, S., Nallasura, V., Hetzel, J. T., Jagadeeswaran, R., Karczmar, G. S., & Salgia, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4416 · Cited by 126
Mills, G. B., Lu, Y., & Kohn, E. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191379498 · Cited by 126
Akeno-Stuart, N., Croyle, M., Knauf, J. A., Malaguarnera, R., Vitagliano, D., Santoro, M., Stephan, C., Grosios, K., Wartmann, M., Cozens, R. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4605 · Cited by 122
“Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation
Sharma, S. V., Fischbach, M. A., Haber, D. A., & Settleman, J. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0096 · Cited by 117
Self-citationTraps to catch unwary oncogenes
Hueber, A., & Evan, G. I. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01520-0 · Cited by 116
Casanova, M., Larcher, F., Casanova, B., Murillas, R., Fernández‐Aceñero, M. J., Villanueva, C., Martínez‐Palacio, J., Ullrich, A., Conti, C. J., & Jorcano, J. L. (2002) · PubMed · Cited by 110
Kim, P. K. M., Armstrong, M. J., Liu, Y., Yan, P., Bucher, B. T., Zuckerbraun, B. S., Gambotto, A. A., Billiar, T. R., & Yim, J. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207023 · Cited by 108
Effect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistance
Kurata, T., Tamura, K., Kaneda, H., Nogami, T., Uejima, H., Asai, G., Nakagawa, K., & Fukuoka, M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdh006 · Cited by 107
Loke, S. L., Stein, C. A., Zhang, X., Avigan, M., Cohen, J. S., & Neckers, L. (1988) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-74006-0_38 · Cited by 103
Groth, A., Weber, J. D., Willumsen, B. M., Sherr, C. J., & Roussel, M. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003417200 · Cited by 102
Yano, S., Nakataki, E., Ohtsuka, S., Inayama, M., Tomimoto, H., Edakuni, N., Kakiuchi, S., Nishikubo, N., Muguruma, H., & Sone, S. (2005) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504005775082020 · Cited by 99
Colomer, R., Lupu, R., Bacus, S. S., & Gelmann, E. P. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.405 · Cited by 99
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
Chen, J., Lee, B. H., Williams, I. R., Kutok, J. L., Mitsiades, C. S., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R. O., Coburn, A., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208989 · Cited by 97
Apoptotic and Growth-Promoting Activity of E2F Modulated by MDM2
Loughran, Ö., & Thangue, N. B. L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.6.2186-2197.2000 · Cited by 93
Drosten, M., & Pützer, B. M. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0610 · Cited by 90
Clarke, K., Smith, K. J., Gullick, W., & Harris, A. L. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1805 · Cited by 89
Paterson, J., Li, Z.-H., Wen, X., Masih-Khan, E., Chang, H., Pollett, J. B., Trudel, S., & Stewart, A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04814.x · Cited by 87
Sini, P., Wyder, L., Schnell, C., O’Reilly, T., Littlewood, A., Brandt, R., Hynes, N. E., & Wood, J. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1954 · Cited by 87
Modulation of c-Myc activity and apoptosis in vivo.
Alarcon, R. M., Rupnow, B. A., Graeber, T. G., Knox, S. J., & Giaccia, A. J. (1996) · PubMed · Cited by 86
Yamazaki, H., Kijima, H., Abe, Y., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.581 · Cited by 85
Garton, A. J., Crew, A. P. A., Franklin, M. R., Cooke, A. R., Wynne, G. M., Castaldo, L., Kahler, J., Winski, S. L., Franks, A., Brown, E. N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2873 · Cited by 85
Yokouchi, H., Yamazaki, K., Kinoshita, I., Konishi, J. S., Asahina, H., Sukoh, N., Harada, M., Akie, K., Ogura, S., Ishida, T., et al. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-51 · Cited by 82
Regulation of both apoptosis and cell survival by the v-Src oncoprotein
Johnson, D., Agochiya, M., Samejima, K., Earnshaw, W. C., Frame, M. C., & Wyke, J. A. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400700 · Cited by 82
Wong, T. W., Lee, F. Y., Yu, C., Luo, F., Oppenheimer, S., Zhang, H., Smykla, R. A., Mastalerz, H. A., Fink, B. E., Hunt, J. T., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0642 · Cited by 78
Moriyama, T., Kataoka, H., Hamasuna, R., Yokogami, K., Uehara, H., Kawano, H., Goya, T., Tsubouchi, H., Koono, M., & Wakisaka, S. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9078 · Cited by 77
White, E., & Stillman, B. (1987) · Journal of Virology · doi:10.1128/jvi.61.2.426-435.1987 · Cited by 72
Younes, M. N., Park, Y. W., Yazici, Y. D., Gu, M., Santillan, A. A., Nong, X., Kim, S., Jasser, S. A., El‐Naggar, A. K., & Myers, J. N. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0228 · Cited by 68
Differential Regulation of Discrete Apoptotic Pathways by Ras
Chen, C., Liou, J. S., Forman, L. W., & Faller, D. V. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.27.16700 · Cited by 63
Dual Growth Arrest Pathways in Astrocytes and Astrocytic Tumors in Response to Raf-1 Activation
Fanton, C. P., McMahon, M., & Pieper, R. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011514200 · Cited by 58
Inhibition of RET tyrosine kinase by SU5416
Mologni, L., Sala, E., Cazzaniga, S., Rostagno, R., Kuoni, T., Puttini, M., Bain, J., Cleris, L., Redaelli, S., Riva, B., et al. (2006) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01999 · Cited by 58
The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis.
Shan, B., Farmer, A. A., & Lee, W. (1996) · PubMed · Cited by 57
Tian, X.-X., Pang, J. C., To, S. S. T., & Ng, H. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199905000-00006 · Cited by 56
Cited by
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Hepatocellular carcinoma: clinical frontiers and perspectives
Bruix, J., Gores, G. J., & Mazzaferro, V. (2014) · Gut · doi:10.1136/gutjnl-2013-306627 · Cited by 1,364
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,005
OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma
Medina, P. P., Nolde, M., & Slack, F. J. (2010) · Nature · doi:10.1038/nature09284 · Cited by 971
Metadata
- Authors
- Sharma, S. V., & Settleman, J.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2007-12-13
- Volume
- 21
- Issue
- 24
- Pages
- 3214-3231
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2123326378
- Cited by
- 441
- References
- 219
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.